Neuroleptic	neuroleptic	O	DISEASE	OTHERS	I
malignant	malignant	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
induced	induced	O	O	O	O
by	by	O	O	O	O
ziprasidone	ziprasidone	O	O	OTHERS	I
on	on	O	O	O	O
the	the	O	O	O	O
second	second	O	O	O	O
day	day	O	O	O	O
of	of	O	O	O	O
treatment	treatment	O	O	O	O
.	.	O	O	O	O

Neuroleptic	neuroleptic	O	DISEASE	OTHERS	I
malignant	malignant	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
(	(	O	O	O	O
NMS	nms	O	O	OTHERS	I
)	)	O	O	O	O
is	is	O	O	O	O
the	the	O	O	O	O
rarest	rarest	O	O	O	O
and	and	O	O	O	O
most	most	O	O	O	O
serious	serious	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
neuroleptic-induced	neuroleptic-induced	O	O	O	O
movement	movement	O	DISEASE	OTHERS	I
disorders	disorders	O	DISEASE	OTHERS	I
.	.	O	O	O	O

We	we	O	O	O	O
describe	describe	O	O	O	O
a	a	O	O	O	O
case	case	O	O	O	O
of	of	O	O	O	O
neuroleptic	neuroleptic	O	DISEASE	OTHERS	I
malignant	malignant	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
(	(	O	O	O	O
NMS	nms	O	O	OTHERS	I
)	)	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
ziprasidone	ziprasidone	O	O	OTHERS	I
.	.	O	O	O	O

Although	although	O	O	O	O
conventional	conventional	O	O	O	O
neuroleptics	neuroleptics	CHEMICALS	O	OTHERS	I
are	are	O	O	O	O
more	more	O	O	O	O
frequently	frequently	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
NMS	nms	O	O	OTHERS	I
,	,	O	O	O	O
atypical	atypical	O	O	O	O
antipsychotic	antipsychotic	CHEMICALS	O	OTHERS	I
drugs	drugs	CHEMICALS	O	OTHERS	I
like	like	O	O	O	O
ziprasidone	ziprasidone	O	O	OTHERS	I
may	may	O	O	O	O
also	also	O	O	O	O
be	be	O	O	O	O
a	a	O	O	O	O
cause	cause	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
patient	patient	O	O	O	O
is	is	O	O	O	O
a	a	O	O	O	O
24-year-old	24-year-old	O	O	O	O
male	male	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
history	history	O	O	O	O
of	of	O	O	O	O
schizophrenia	schizophrenia	O	DISEASE	OTHERS	I
who	who	O	O	O	O
developed	developed	O	O	O	O
signs	signs	O	DISEASE	OTHERS	I
and	and	O	DISEASE	OTHERS	I
symptoms	symptoms	O	DISEASE	OTHERS	I
of	of	O	O	O	O
NMS	nms	O	O	OTHERS	I
after	after	O	O	O	O
2	2	O	O	O	O
days	days	O	O	O	O
of	of	O	O	O	O
treatment	treatment	O	O	O	O
with	with	O	O	O	O
an	an	O	O	O	O
80-mg/day	80-mg/day	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
orally	orally	O	O	O	O
administrated	administrated	O	O	O	O
ziprasidone	ziprasidone	O	O	OTHERS	I
.	.	O	O	O	O

This	this	O	O	O	O
case	case	O	O	O	O
is	is	O	O	O	O
the	the	O	O	O	O
earliest	earliest	O	O	O	O
(	(	O	O	O	O
second	second	O	O	O	O
day	day	O	O	O	O
of	of	O	O	O	O
treatment	treatment	O	O	O	O
)	)	O	O	O	O
NMS	nms	O	O	OTHERS	I
due	due	O	O	O	O
to	to	O	O	O	O
ziprasidone	ziprasidone	O	O	OTHERS	I
reported	reported	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
literature	literature	O	O	O	O
.	.	O	O	O	O

